Mark Sleeman resumes & CV records
Resumes
Mark Sleeman
Mark Beth Ann Sleeman
Mark L Sleeman
Mark W Sleeman, Age 6711 Lake Rd, Mahopac, NY 10541
Mark Sleeman Phones & Addresses
11 Lake Rd, Mahopac, NY 10541 (845) 621-0053
118 Lake Rd, Mahopac, NY 10541 (845) 621-0053
611 Barrett Hill Rd, Mahopac, NY 10541 (914) 621-0053
Carmel, NY
Brewster, NY
Grafton, MA
3086 Weston Ln, Yorktown Heights, NY 10598 (914) 245-9163
North Grafton, MA
611 Barrett Hill Rd, Mahopac, NY 10541
Work
Position:
Professional/Technical
Education
Degree:
Graduate or professional degree
Mentions for Mark W Sleeman
Publications & IP owners
Us Patents
Methods Of Treating Diabetes By Blocking Vegf-Mediated Activity
US Patent:
7052691, May 30, 2006
Filed:
Mar 26, 2004
Appl. No.:
10/811170
Inventors:
Mark W. Sleeman - Mahopac NY, US
Stanley J. Wiegand - Croton-on-Hudson NY, US
Stanley J. Wiegand - Croton-on-Hudson NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A61K 38/18
C07K 14/71
C12N 15/62
C07K 14/71
C12N 15/62
US Classification:
4241341, 4241921, 514 2, 514 12, 530350, 5303873, 536 234
Abstract:
Methods of treating diabetes in mammals, particularly humans, by blocking or inhibiting VEGF-mediated activity. A preferred inhibitor of VEGF-mediated activity is a VEGF antagonist such as a VEGF trap capable of binding and blocking VEGF.
Methods Of Treating Type I Diabetes By Blocking Vegf-Mediated Activity
US Patent:
7378095, May 27, 2008
Filed:
Jul 29, 2005
Appl. No.:
11/193746
Inventors:
Jingtai Cao - Chappaqua NY, US
Li-Hsien Wang - Somers NY, US
Hsin Chieh Lin - Yorktown Heights NY, US
Mark W. Sleeman - Mahopac NY, US
Stanley J. Wiegand - Croton-on-Hudson NY, US
Li-Hsien Wang - Somers NY, US
Hsin Chieh Lin - Yorktown Heights NY, US
Mark W. Sleeman - Mahopac NY, US
Stanley J. Wiegand - Croton-on-Hudson NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A61K 38/18
C07K 14/71
C12N 15/62
C07K 14/71
C12N 15/62
US Classification:
4241341, 4241921, 514 2, 514 12, 530350, 536 234
Abstract:
Methods of treating diabetes in mammals, particularly humans, by blocking or inhibiting VEGF-mediated activity. A preferred inhibitor of VEGF-mediated activity is a VEGF antagonist such as the VEGF fusion protein trap of SEQ ID NO:2 capable of binding and blocking VEGF. The method of the invention may be combined with other therapies, such as with insulin therapy.
High Affinity Human Antibodies To Pcsk9
US Patent:
8062640, Nov 22, 2011
Filed:
Dec 15, 2009
Appl. No.:
12/637942
Inventors:
Mark W. Sleeman - Mahopac NY, US
Joel H. Martin - Putnam Valley NY, US
Tammy T Huang - Goldens Bridge NY, US
Douglas MacDonald - New York NY, US
Joel H. Martin - Putnam Valley NY, US
Tammy T Huang - Goldens Bridge NY, US
Douglas MacDonald - New York NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A61K 39/395
C07K 16/00
C12P 21/08
C07K 16/00
C12P 21/08
US Classification:
4241581, 5303871, 5303879
Abstract:
An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.
Human Antibodies To Human Angiopoietin-Like Protein 4
US Patent:
8354103, Jan 15, 2013
Filed:
Dec 23, 2010
Appl. No.:
12/977361
Inventors:
Mark W. Sleeman - Mahopac NY, US
Viktoria Gusarova - Springfield NJ, US
Jee H. Kim - White Plains NY, US
Gang Chen - Yorktown Heights NY, US
Viktoria Gusarova - Springfield NJ, US
Jee H. Kim - White Plains NY, US
Gang Chen - Yorktown Heights NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A61K 39/395
C07K 16/28
C07K 16/28
US Classification:
4241301, 5303871, 5303881, 53038822
Abstract:
A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human angiopoietin-like protein 4 (hANGPTL4) is provided. The human anti-hANGPTL4 antibodies are useful in treating diseases or disorders associated with ANGPTL4, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL4 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.
Methods For Treating Hypercholesterolemia Using Antibodies To Pcsk9
US Patent:
8357371, Jan 22, 2013
Filed:
Apr 27, 2011
Appl. No.:
13/095234
Inventors:
Mark W. Sleeman - Mahopac NY, US
Joel H. Martin - Putnam Valley NY, US
Tammy T. Huang - Goldens Bridge NY, US
Douglas MacDonald - New York NY, US
Gary Swergold - New Rochelle NY, US
Joel H. Martin - Putnam Valley NY, US
Tammy T. Huang - Goldens Bridge NY, US
Douglas MacDonald - New York NY, US
Gary Swergold - New Rochelle NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A61K 39/395
C07K 16/00
C12P 21/08
C07K 16/00
C12P 21/08
US Classification:
4241581, 5303871, 5303879
Abstract:
The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an anti-PCSK9 antibody or antigen-binding fragment thereof.
High Affinity Human Antibodies To Pcsk9
US Patent:
8501184, Aug 6, 2013
Filed:
Nov 19, 2010
Appl. No.:
12/949846
Inventors:
Mark W. Sleeman - Mahopac NY, US
Joel H. Martin - Putnam Valley NY, US
Tammy T. Huang - Goldens Bridge NY, US
Douglas MacDonald - New York NY, US
Joel H. Martin - Putnam Valley NY, US
Tammy T. Huang - Goldens Bridge NY, US
Douglas MacDonald - New York NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A61K 39/395
C07K 16/00
C12P 21/08
C07K 16/00
C12P 21/08
US Classification:
4241581, 5303871, 5303879
Abstract:
An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.
Therapeutic Method For Combined Use Of Modified Cntf And Thiadolidinedione
US Patent:
2004003, Feb 19, 2004
Filed:
Aug 12, 2003
Appl. No.:
10/639107
Inventors:
Mark Sleeman - Mahopac NY, US
International Classification:
A61K038/18
A61K031/4439
A61K031/426
A61K031/4439
A61K031/426
US Classification:
514/012000, 514/342000, 514/369000
Abstract:
A combined therapy for the treatment of non-insulin dependent diabetes mellitus (NIDDM) with ciliary neurotrophic factor (CNTF) or a modified CNTF, and a thiazolidinedione.
Method Of Treating Liver Steatosis In A Mammal
US Patent:
2004014, Jul 22, 2004
Filed:
Jan 16, 2004
Appl. No.:
10/758783
Inventors:
Mark Sleeman - Mahopac NY, US
International Classification:
A61K038/18
US Classification:
514/012000
Abstract:
Methods of treating, inhibiting, and/or ameliorating liver steatosis in a subject in need thereof, comprising adminstering an agent capable of activating a ciliary neurotrophic factor (CNTF) receptor.
NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.